Ziel Biopharma (Ltd) is an innovative biopharmaceutical company whose core technology is the encapsulation of living cells for a variety of therapeutic purposes using Sodium Cellulose Sulphate (SCS).  Ziel Biopharma Ltd is dedicated to research and development of innovative cell therapeutic drugs against diseases with high clinical unmet needs including cancer, diabetes and cardio-vascular disease.

Ziel Biopharma Ltd is part of Ryan Group Holdings, based in Limerick, Ireland, with an office in Vienna, Austria.  Ziel Biopharma Ltd provides an encapsulation service to the pharmaceutical industry, lifescience companies, biotechnology companies' researchers and academics.

This unique drug delivery system allows for targeted therapy and can be used for the treatment of many diseases through the encapsulation of cells for therapeutic purposes, including: Cardiology, Immunology, Inherited Diseases, and Infectious Diseases.

"Ziel encapsulates cells in a protecting polymer for therapeutic use. The collaboration with REMEDI is an important initiative in an area of unmet medical need." 

Gerard Ryan, CEO, Ziel Biopharma

For more information, visit www.zielbiopharma.com